Terlipressin is a synthetic analogue of vasopressin used as a vasoactive drug to manage low blood pressure, particularly in cases where norepinephrine is ineffective.
In terms of its mechanism of action, Terlipressin mimics endogenous vasopressin, exhibiting increased selectivity for the V1 receptor and a longer half-life. It increases systemic vascular resistance, particularly in the splanchnic area, reducing portal pressure. This leads to increased arterial pressure and decreased heart rate in patients with hepatorenal syndrome. The drug is metabolized by tissue peptidases to its active form, lysine-vasopressin, which exerts vasoconstrictive and antidiuretic effects.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | glypressin, glycylpressin |
|---|---|
| IUPAC Name | (2S)-1-[(4R, 7S, 10S, 13S, 16S, 19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6, 9, 12, 15, 18-pentaoxo-1, 2-dithia-5, 8, 11, 14, 17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide |
| CAS | 14636-12-5 |
| Molecular Weight | 1227.4 |
| Molecular Formula | C52H74N16O15S2 |
| SMILES | C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N |